Salbutamol and Ipratropium Bromide are to be Prescribed with Caution by Nursing Staff Which are Risk Factors for Arrhythmias in Patients with CVS Diseases

Abstract

Arrhythmias are well linked with increased deaths in all types of patients. This study examines the effects of salbutamol and ipratropium bromide on developing risk of arrhythmias in the population of Armenia with history of CVS ailment. Methods: The design was a case-control study in 40 adult patients who presented with exacerbation of COPD, out of which, 20 were males and 20 were females of mean age group of 55 years. Out of them, 10 male and 10 female patients were known cases of different CVS ailments and others were not. Patients in Group A were numbered from 1 to 20 and Group B was numbered from 21 to 40. Patients were taking the SABA, ipratropium bromide and ICS with on-and-off basis for the past 3–4 years as their treatment for COPD. And the history was taken for any arrhythmias or ECG changes. Seven cases of arrhythmias occurred in group A in which four males and three females were recognized. Five of them had premature ventricular contractions. Only two patients, one male and one female, were stopped with treatment because of the development of atrial fibrillation and only one female developed arrhythmia in group B. Results: With the above-mentioned data, odds ratio of +10.23 was calculated, and considering the vitals monitored during the treatment as well, it simply explains the fact that salbutamol and ipratropium bromide have the potential to aggravate and cause arrhythmias in patients with CVS ailments. Conclusion: Treating patients with beta 2-adrenergic receptors agonist and anticholinergic drug can be pharmacologically aggravating the risk of development arrhythmias in already CVS- and respiratory-compromised patients, and should be avoided or given with lots of caution and under strict monitoring.